Unlocking Profitability: Plus Therapeutics to Present Data from Ongoing Clinical Trials at 35th Annual Congress of the European Association of Nuclear Medicine
Top Rated Oral Presentation: Leptomeningeal Metastases Data Expertise in Rare and Difficult-to-Treat Cancers Plus Therapeutics, Inc. has been recognized for its groundbreaking work in developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers. With a sharp focus on profitability and expertise in the field, the company continues to push the boundaries of what is possible…